Article
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility.
Oncotarget - 28 Aug 2015
Alvi Muhammad A, McArt Darragh G, Kelly Paul, Fuchs Marc-Aurel, Alderdice Matthew, McCabe Clare M, Bingham Victoria, McGready Claire, Tripathi Shailesh, Emmert-Streib Frank, Loughrey Maurice B, McQuaid Stephen, Maxwell Perry, Hamilton Peter W, Turkington Richard, James Jacqueline A, Wilson Richard H, Salto-Tellez Manuel
Abstract excerpt
Small bowel accounts for only 0.5% of cancer cases in the US but incidence rates have been rising at 2.4% per year over the past decade. One-third of these are adenocarcinomas but little is known about their molecular pathology and no molecular markers are available for clinical use. Using a retrospective 28 patient matched normal-tumor cohort, next-generation sequencing, gene expression arrays and CpG...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
